| abstract |
The invention relates to iRNA, e.g., double-stranded nribonucleic acid (dsRNA), compositions targeting the n5 complement component C5 gene, and methods of using such niRNA, e.g., dsRNA, compositions to inhibit expression of nC5 and to treat subjects having a complement component C5nassociated disease, e.g., paroxysmal nocturnal nhemoglobinuria. nC:\NRPortbl\GHMatters\MICHELES\11870056_1.docx 12/11/19 |